Lee Mary R, Wehring Heidi J, McMahon Robert P, Liu Fang, Linthicum Jared, Verbalis Joseph G, Buchanan Robert W, Strauss Gregory P, Rubin Leah H, Kelly Deanna L
National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, Bethesda, MD, United States.
Maryland Psychiatric Research Center, University of Maryland School of Medicine, United States.
Schizophr Res. 2016 Apr;172(1-3):165-8. doi: 10.1016/j.schres.2016.02.014. Epub 2016 Feb 12.
Several clinical studies have found an inverse relationship between clinical symptoms and peripheral oxytocin (OT) levels in people with schizophrenia. As oxytocin is a putative treatment for schizophrenia, the effect of repeated dosing of OT on OT levels, clinical symptoms and the relationship between the two is of interest. In a, randomized, double blind, parallel group 3 week study (N=28) with daily administration of intranasal OT (20 IU twice daily) or placebo (PBO), we examined the effect of OT administration on the correlation between the change in peripheral OT levels and change in clinical symptoms in patients with schizophrenia. At baseline, there were no significant treatment group differences in OT levels. There were no significant associations between baseline OT levels and any symptom measures. After 3 weeks of OT/PBO dosing, there was no significant difference in the magnitude of change in OT levels between the two treatment groups. Correlations between changes in peripheral OT levels and changes in the BPRS total and negative symptom scores were not different between treatment groups. Larger studies are needed to examine the effect of exogenous OT on peripheral OT levels and the relationship between the latter and clinical symptoms. Clinical Trials.gov=NCT00884897.
多项临床研究发现，精神分裂症患者的临床症状与外周催产素（OT）水平之间存在负相关关系。由于催产素被认为是治疗精神分裂症的一种药物，反复给药催产素对OT水平、临床症状以及两者之间关系的影响备受关注。在一项为期3周的随机、双盲、平行组研究（N = 28）中，每日给予鼻内催产素（20国际单位，每日两次）或安慰剂（PBO），我们研究了催产素给药对精神分裂症患者外周OT水平变化与临床症状变化之间相关性的影响。在基线时，各治疗组的OT水平无显著差异。基线OT水平与任何症状指标之间均无显著关联。在给予催产素/安慰剂3周后，两个治疗组之间OT水平变化的幅度无显著差异。治疗组之间外周OT水平变化与简明精神病评定量表（BPRS）总分及阴性症状评分变化之间的相关性无差异。需要开展更大规模的研究来考察外源性催产素对外周OT水平的影响以及后者与临床症状之间的关系。临床试验注册号：NCT00884897。
